The German Cancer Aid is funding the cancer research project "Onkogene Transkription als Zielstruktur für neue Krebstherapien (TACTIC)" with around 11.8 million euros. This Germany-wide research network establishes platforms for drug development and develops new small molecule-based therapy concepts. In this context, the development of proteolysis targeting chimeras (PROTACs) also plays an important role. Speaker of this project is PROXIDRUGS project leader Prof. Dr. Stefan Knapp from the Institute of Pharmaceutical Chemistry at Goethe University Frankfurt am Main.